BCAX 10-Q: SEC filing
Bicara Therapeutics Inc.
Filed with the SEC on · accession 0001628280-26-072169
BCAX filed a 10-Q (quarterly report) with the SEC on Nov 9, 2026. The quarterly report: unaudited results for the quarter plus management’s comments. The stock moved +8.5% by the first close after the filing.
Summary of the filing
Bicara Therapeutics Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, reporting financial results and corporate updates including a February 2026 equity offering and an at-the-market (ATM) program.
Key details
How BCAX stock reacted
Close before
$8.65
Nov 6, 2026
First close after
+8.50%
$9.38
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for BCAX, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for BCAX?
Click hereFrequently asked questions
What did BCAX file with the SEC on Nov 9, 2026?
BCAX filed a 10-Q (SEC filing). Bicara Therapeutics Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, reporting financial results and corporate updates including a February 2026 equity offering and an at-the-market (ATM) program.
How do I read a 10-Q?
The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.
How did BCAX stock react to this filing?
BCAX closed at $8.65 before the filing and $9.38 on Nov 9, 2026 (+8.50%).
Other BCAX SEC filings
- 8-K · SEC filingNov 9, 2026
- SCHEDULE 13G/A · SEC filingOct 7, 2026
- 8-K · SEC filingAug 25, 2026
- SCHEDULE 13G/A · SEC filingAug 13, 2026
- 8-K · SEC filingAug 11, 2026
- 10-Q · SEC filingAug 11, 2026
- 8-K · Board changeJul 28, 2026
- 144 · Insider sale plannedJul 10, 2026
- 8-K · Board changeJun 10, 2026
- 8-K · Fda approvalMay 21, 2026
Get alerts when BCAX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days